| pubmed-article:12201361 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C0013018 | lld:lifeskim |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C1333568 | lld:lifeskim |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C0005953 | lld:lifeskim |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C0450127 | lld:lifeskim |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C1282910 | lld:lifeskim |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C0167627 | lld:lifeskim |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C0205307 | lld:lifeskim |
| pubmed-article:12201361 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:12201361 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:12201361 | pubmed:dateCreated | 2002-8-30 | lld:pubmed |
| pubmed-article:12201361 | pubmed:abstractText | Flt3 ligand (FL) administration markedly increases bone marrow (BM) stem cells and immature dendritic cells. We investigated the influence of CD40-CD40Ligand (CD154) pathway blockade on antidonor immunity, cytokine production, microchimerism and heart graft survival in BALB/c (H2d) recipients of fully allogeneic C57BL/10 (H2b) FL-mobilized BM (FL-BM) or normal BM. Anti-CD40L mAb strongly suppressed anti-donor T-cell proliferative responses in recipients of either normal or FL-BM, but was less efficient in inhibiting antidonor cytolytic T-cell (CTL) activity, especially in recipients of FL-BM. Interestingly, CD40L blockade was more effective in recipients of multiple compared with single donor BM infusions. Anti-donor cytokine responses revealed complete impairment of IFN-gamma, IL-4 and IL-10 production in recipients of normal BM and CD40L mAb. By contrast, and in agreement with the CTL data, mice given FL-BM retained ability to produce IFN-gamma CD40-CD40L blockade did not promote microchimerism, as evidenced by immunohistology and real time polymerase chain reaction. Nevertheless, anti-CD40L mAb enhanced heart allograft survival in recipients of FL-BM, but the effect was inferior to that achieved with normal BM. These data provide insight into the influence of growth factor-expanded donor BM and costimulation blockade on antidonor immune reactivity and transplant outcome. The comparatively poor outcome obtained using FL-BM plus anti-CD40L mAb in this model may be ascribed to the failure of effectively interdicting antidonor CTL activity. | lld:pubmed |
| pubmed-article:12201361 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12201361 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12201361 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12201361 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12201361 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12201361 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12201361 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12201361 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12201361 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12201361 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12201361 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12201361 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:12201361 | pubmed:issn | 1600-6135 | lld:pubmed |
| pubmed-article:12201361 | pubmed:author | pubmed-author:WangZhiliangZ | lld:pubmed |
| pubmed-article:12201361 | pubmed:author | pubmed-author:ThomsonAngus... | lld:pubmed |
| pubmed-article:12201361 | pubmed:author | pubmed-author:HacksteinHolg... | lld:pubmed |
| pubmed-article:12201361 | pubmed:author | pubmed-author:TakayamaTakuy... | lld:pubmed |
| pubmed-article:12201361 | pubmed:author | pubmed-author:KanekoKatsuhi... | lld:pubmed |
| pubmed-article:12201361 | pubmed:author | pubmed-author:MorelliAdrian... | lld:pubmed |
| pubmed-article:12201361 | pubmed:author | pubmed-author:ColvinBridget... | lld:pubmed |
| pubmed-article:12201361 | pubmed:author | pubmed-author:BeinGregorG | lld:pubmed |
| pubmed-article:12201361 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12201361 | pubmed:volume | 2 | lld:pubmed |
| pubmed-article:12201361 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12201361 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12201361 | pubmed:pagination | 609-17 | lld:pubmed |
| pubmed-article:12201361 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:meshHeading | pubmed-meshheading:12201361... | lld:pubmed |
| pubmed-article:12201361 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12201361 | pubmed:articleTitle | Normal donor bone marrow is superior to Flt3 ligand-mobilized bone marrow in prolonging heart allograft survival when combined with anti-CD40L (CD154). | lld:pubmed |
| pubmed-article:12201361 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12201361 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12201361 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12201361 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12201361 | lld:pubmed |
